RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on CRPC

Apr 23 2010

Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for the treatment of CRPC are lacking, and a number of factors must be considered when deciding between second-line hormonal therapy and chemotherapy. There are also a number of therapies being investigated in clinical trials for CRPC. It is critical for healthcare professionals involved in the care of patients with CRPC to understand and utilize the current optimal methods for defining and treating this condition, as well as be aware of emerging therapies under investigation.

To address the need for current education on CRPC, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education virtual lecture titled Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease. The content of this virtual lecture is derived from a live webcast that took place on March 25, 2010. This activity, which is supported by educational grants from sanofi-aventis and Genentech, is certified for physicians, pharmacists, and nurses.